Chronic Kidney Disease Monitoring and Follow-up
About
Chronic kidney disease (CKD) monitoring and follow-up is a planned series of clinical reviews and selected tests for people with established CKD. Its purpose is to identify meaningful changes in kidney health, evaluate the risk of progression, assess treatment safety and recognize complications early enough to guide care. This differs from a first-time consultation to establish why a kidney test is abnormal. Patients living with CKD can send previous blood and urine results through ZagrebMed to inquire about an appropriate follow-up assessment in Zagreb.
Key facts
- Main purpose: Monitor established CKD, risk trends, complications and treatment safety.
- Core markers: Blood creatinine with eGFR and urine albumin-to-creatinine ratio (uACR).
- Monitoring frequency: At least annually for many patients with CKD; more often according to individual risk and care decisions.
- Other checks: Blood pressure, medications, blood count, electrolytes and mineral parameters when indicated.
- Clinical decisions: Individualized treatment, specialist referral and follow-up intervals.
- Urgent signs: Severe breathlessness, rapidly reduced urine output or sudden serious deterioration.
What is chronic kidney disease follow-up?
CKD describes abnormalities of kidney structure or function with implications for health that have generally persisted for at least three months. Not everyone with CKD progresses to kidney failure. The outlook depends on the cause, estimated filtration, urine albumin, associated conditions and changes over time. Follow-up therefore focuses on a person's individual situation instead of using the same plan for every patient.
How doctors assess CKD stage and risk
Clinicians usually describe CKD by its cause, glomerular filtration category (G1–G5) and albuminuria category (A1–A3). This cause–GFR–albuminuria approach helps distinguish someone with preserved filtration but substantial albuminuria from a person with reduced filtration and little albumin loss. Serum creatinine is measured and an estimated glomerular filtration rate (eGFR) is calculated, while the urine albumin-to-creatinine ratio (uACR) assesses albumin loss.
A nephrology consultation may be necessary if the underlying diagnosis is uncertain, kidney function changes rapidly, urine findings are unusual or treatment choices become complex. Where appropriate in CKD G3–G5, clinicians can use validated kidney-failure risk equations in addition to clinical judgment. Risk estimates inform decisions but cannot predict the exact outcome for an individual.
Which blood and urine tests are monitored?
The central measurements are eGFR and urine albumin. The KDIGO 2024 guideline advises checking both at least annually in people with CKD, with more frequent assessments for those at higher risk or when results will influence treatment. A clinician may repeat a test sooner after a significant change, an acute illness or the introduction of medicine requiring monitoring. Small fluctuations in creatinine and albumin can occur and should not automatically be interpreted as deterioration.
Other measurements depend on the disease stage, treatment and suspected complications. They may include potassium and other electrolytes, bicarbonate, blood count, calcium, phosphate, glucose or HbA1c and selected tests of mineral metabolism. Not every laboratory parameter is needed at every visit. The kidney function and urine tests section explains what the primary investigations measure and why ordinary urinalysis does not replace uACR.
Managing blood pressure, diabetes and cardiovascular risk
High blood pressure and diabetes are common causes of CKD and may also accelerate progression. During follow-up, the medical team reviews blood pressure measurements, diabetes management, heart and vascular risks, smoking status and medicines. Blood pressure targets are individualized according to age, tolerability, comorbidities and the measurement method. Patients may be asked to provide home readings rather than judging control from one clinic measurement.
Medication strategies can include renin–angiotensin system blockers or SGLT2 inhibitors for appropriately selected patients under current evidence-based recommendations. These drugs are not suitable for every person and need consideration of kidney function, albuminuria, potassium, diabetes, heart failure, pregnancy-related factors and other conditions. Follow-up assesses benefits, adverse effects and laboratory changes; a patient should not start, stop or change prescription medicine independently.
Reviewing medicines and preventing avoidable kidney injury
CKD can change how certain medicines are handled by the body. A clinician or pharmacist may review prescription drugs, over-the-counter pain relievers, herbal preparations, contrast exposure and supplements, including creatine. Some medicines need dose adjustment or extra laboratory checks, while others may be unsuitable in particular clinical situations. The purpose is safer care, not to stop all treatment that may affect kidney laboratory values.
During dehydration, severe infection or other acute illness, kidney function can change quickly and urgent reassessment may be necessary. Patients should discuss with their care team whether they need an individualized plan for medicine use during intercurrent illness. General internet advice to stop all blood pressure or diabetes drugs can be unsafe. Medication decisions should always be specific to the person and clinical circumstances.
Monitoring anemia, minerals and other complications
CKD may be associated with anemia, changes in mineral and bone metabolism, abnormal potassium levels, acid–base disturbances, fluid retention and cardiovascular problems. A clinician evaluates symptoms such as fatigue, breathlessness, swelling, muscle weakness or changes in appetite, alongside objective tests when indicated. Such symptoms have many possible causes, and their presence does not by itself prove that kidney disease has progressed.
The choice and frequency of investigations depend on the disease stage and previous findings. A blood count may help assess anemia; iron tests can be indicated when anemia is present. Calcium, phosphate and parathyroid hormone can be relevant to CKD-related mineral and bone disorders in selected patients. Potassium and bicarbonate monitoring may be important for specific medicines or more advanced CKD. Care is coordinated with other specialists when necessary.
Nutrition, activity and living with CKD
Patients may benefit from an individualized approach to sodium intake, overall nutrition, physical activity, weight management and smoking cessation. A renal diet is not one universal list of forbidden foods. Protein, potassium, phosphate and fluid recommendations should reflect kidney function, actual laboratory results, nutritional status and any dialysis treatment. Unnecessary restriction may lead to malnutrition, especially in older or medically vulnerable people.
Physical activity suited to the person's ability and cardiovascular health can support well-being. Changes in diet should be made with a qualified clinician or renal dietitian when complex restrictions are needed. A person experiencing edema, unusual breathlessness or major changes in urine output should ask for a medical assessment rather than trying to correct the problem independently through large changes in fluid or food intake.
When is a higher level of kidney care needed?
Some patients remain stable for years with shared care between primary care and nephrology. Others need closer specialist follow-up because albuminuria increases, eGFR falls, blood pressure is difficult to control or complications develop. The KDIGO guideline supports using validated kidney-failure risk estimates for appropriate adults with CKD G3–G5 when deciding on specialist referral and multidisciplinary care. The plan also takes into account symptoms, comorbidities and patient preferences.
Advanced CKD can require education about treatment options, future access planning or transplant assessment. Hemodialysis and peritoneal dialysis are separate kidney replacement pathways and are not automatically necessary when a particular eGFR threshold is reached. Decisions reflect symptoms, metabolic and fluid complications, overall condition and shared decision-making with the specialist. Routine follow-up should not be confused with acute or critical-care dialysis.
Planning your follow-up through ZagrebMed
To inquire about follow-up in Zagreb, share the reason for the assessment, the original kidney diagnosis if known, recent and previous eGFR and uACR values with dates, blood pressure readings and a list of medicines. Mention diabetes, cardiovascular disease, previous imaging and any previous nephrology recommendations. The clinician can then determine whether a follow-up visit, additional laboratory tests or another investigation is appropriate.
Patients traveling from abroad can share documents ahead of a visit and discuss how subsequent monitoring might be coordinated with clinicians at home. No fixed schedule or same-day workup should be assumed. Severe shortness of breath, chest pain, confusion, rapidly declining urine output or significant sudden deterioration requires urgent medical assessment rather than a routine ZagrebMed inquiry.
Candidate
People with an established diagnosis of chronic kidney disease who require follow-up of eGFR, urine albumin, blood pressure, complications or medication safety. More intensive monitoring may be needed with declining renal function, substantial albuminuria, diabetes, hypertension or clinical changes. A first-time uncertain diagnosis may instead require an initial nephrology consultation.
Preparation
Bring earlier laboratory reports with dates and units, particularly creatinine/eGFR and urine uACR, plus blood pressure records, medication and supplement lists, diagnoses and prior nephrology advice. The clinician selects the tests and any fasting or urine sampling instructions. Do not change medication, hydration or dietary restrictions without medical guidance.
Treatment
Follow-up usually involves reviewing symptoms, kidney laboratory trends, blood pressure, associated conditions and medication safety. A clinician chooses blood or urine tests and, when needed, imaging or assessment for CKD complications. The visit leads to a personalized monitoring and treatment plan rather than a standardized procedure or guaranteed clinical result.
Result
The assessment may clarify CKD stage, albuminuria category, rate of change, complication risk and whether the current management plan remains appropriate. A clinician can recommend follow-up intervals, treatment review or specialist referral. Results do not guarantee that CKD will stop progressing and one test does not determine prognosis.
Precautions
Unexpectedly changed kidney results, high potassium or symptoms of fluid overload may need prompt professional assessment. Do not stop or start prescribed drugs based on online information. Routine CKD monitoring is not a substitute for emergency care when there is severe breathlessness, chest pain, confusion, sudden major reduction in urination or rapid deterioration.
Steps
Share your CKD history and previous results
Before the appointment, provide the diagnosis if known, earlier creatinine/eGFR and urine albumin results with dates, home blood pressure readings, medicines and other relevant conditions. The clinician determines which questions should be addressed and whether additional laboratory testing is needed before or after the review.
Review kidney trends, risks and complications
The clinician evaluates the course of kidney function and albuminuria, blood pressure, medicine safety and possible complications. Depending on previous results and symptoms, further blood or urine testing or other specialist input may be recommended. No single test or fixed sequence applies to everyone with CKD.
Agree on an individualized follow-up plan
You receive an explanation of the results, meaningful changes and potential treatment or lifestyle adjustments. The clinician sets appropriate monitoring intervals and identifies findings that should trigger earlier reassessment. When necessary, nephrology, primary care and other specialists coordinate management, including planning for advanced disease without assuming dialysis is inevitable.
F.A.Q.
KDIGO 2024 advises measuring eGFR and albuminuria at least annually in people with CKD. Those at higher risk, with changing results or new treatments may need more frequent testing. A clinician sets the schedule.
eGFR estimates how well kidneys filter blood. uACR measures albumin lost in the urine, an indicator of possible kidney damage. Both contribute to CKD classification and risk assessment.
No. Many people with CKD never require kidney replacement treatment. Dialysis or transplant options are considered only when clinically appropriate in advanced disease and after specialist assessment.
For selected patients, blood pressure management and evidence-based medicines can reduce the risk of progression. Diet and activity recommendations should reflect laboratory findings and health conditions. No one treatment works for everyone.
You can send earlier laboratory reports, diagnoses and prescriptions through ZagrebMed to inquire about an assessment in Zagreb. The follow-up plan should be coordinated with your usual healthcare professionals and available providers.

Send an inquiry for the treatment
Start your way towards a successful treatment today. Fill out the form with your data, choose the service you need and we will connect you with the top medical experts in Zagreb.